Finance
BioNTech lifts 2025 revenue guidance on BMS partnership payment
Published by Global Banking & Finance Review®
Posted on November 3, 2025
1 min readLast updated: January 21, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on November 3, 2025
1 min readLast updated: January 21, 2026
BioNTech boosts 2025 revenue forecast after BMS partnership payment, focusing on cancer drugs as COVID-19 vaccine revenue declines.
FRANKFURT (Reuters) -Germany's BioNTech on Monday lifted its 2025 revenue guidance after receiving initial payments from its new partner Bristol Myers Squibb in a cancer immunotherapy alliance that seeks to challenge Merck's best-selling Keytruda.
BioNTech, Pfizer's partner on COVID-19 vaccines, said it was projecting full-year revenue of 2.6 billion euros ($3.03 billion) to 2.8 billion euros, up from a previous guidance range of 1.7 billion to 2.2 billion euros.
Earlier this year, Bristol agreed to pay up to $11.1 billion in the partnership deal over time, depending on achievements.
BioNTech said on Monday that the partners extended their clinical trial programme for the cancer drug in question, pumitamig, during the third quarter and would add more trials by next year.
The German biotech firm said third-quarter revenue gained 22% to 1.52 billion euros.
BioNTech is pivoting its focus to cancer drugs, which are expected to drive future growth of the company, as revenue from its COVID-19 vaccine steadily decline from their pandemic era highs.
($1 = 0.8575 euros)
(Reporting by Ludwig Burger in Frankfurt and Bhanvi Satija in London, Editing by Miranda Murray)
A partnership in business refers to a formal arrangement where two or more parties collaborate to manage and operate a business, sharing profits and responsibilities.
Explore more articles in the Finance category
